Podcasts about Cart

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

In this week's episode of the Blood podcast, editor Dr. James Griffin interviews Drs. Christian Gorzelanny and Rebecca Leaf on their latest articles published in this week's issue of Blood. Dr. Gorzelanny discusses compelling evidence for a new mechanism that amplifies their proinflammatory actions in "Lipid nanotubes unmask neutrophils for complement attack", demonstrating the pathological role of this process in a range of inflammatory disorders in order to stimulate intense study of how to regulate nanotube formation for therapeutic benefit. In "Immune thrombocytopenia in patients treated with immune checkpoint inhibitors" Dr. Leaf and colleagues define the incidence, clinical features, and outcomes of ICI-induced immune thrombocytopenia. Showing that ICI-induced immune thrombocytopenia is associated with excess mortality, these data should provide an impetus to greater recognition and to protocolization of effective interventions.

A 10h, ce mercredi 18 mars 2026, les GG : Emmanuel de Villiers, chef d'entreprise, Fatima Aït Bounoua, professeur de français, et Antoine Diers, consultant auprès des entreprises, débattent de : Le RN écarté des alliances... l'union à droite, utopique ?

175 MS activists are heading to Washington, D.C. next week for the National MS Society's Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Capitol Hill.  When it comes to the legislative support for healthcare and medical research, it's no secret that these are unusual times. Joining me to brief us on the National MS Society's ongoing advocacy efforts and give us a sneak peek at the specific legislative issues we'll be taking to Capitol Hill is the National MS Society's Vice President of Advocacy, Steffany Stern. We'll also share updated results from an important study that show the risk of developing MS if a close relative is living with the disease is significantly higher than researchers originally thought. And we'll give you all the details of a Phase 1 clinical trial that's focused on a novel approach to CAR-T cell therapy for MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Preparing for the MS Society's Public Policy Conference  :22 I'm asking for your support:  1:37 An update to a 2015 study shows close relatives of people living with MS are 100 times more likely than the general population to develop MS  2:15 A novel approach to CAR-T cell therapy for MS is recruiting for a Phase 1 clinical trial   4:26 Steffany Stern, the Vice President of Research at the National MS Society, shares a major advocacy win and previews next week's Public Policy Conference in Washington, D.C.  7:27 Share this episode  33:04 Next week  33:25 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/446 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms JOIN: Become an MS Activist https://nationalmssociety.org/advocacy STUDY: A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies https://onlinelibrary.wiley.com/doi/10.1002/acn3.70340 GEMS Study Recruitment https:/nationalmssociety.org/news-and-magazine/news/ms-study-alert-gems RealTalk MS Ep. 439: Preventing MS with Dr. Bruce Bebo https://realtalkms.com/439 PARTICIPATE: A Study to Assess the Safety and Clinical of Azer-cel in Participants with B-cell Mediated Autoimmune Disorders https://clinicaltrials.gov/study/NCT06680037/#contacts-and-locations JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 446 Guests: Steffany Stern Privacy Policy

El programa 'Herrera en COPE', en su sección 'La Hora de los Fósforos' presentada por Alberto Herrera, ha abierto los micrófonos a los oyentes para compartir sus experiencias con bromas pesadas. Entre las numerosas anécdotas, ha destacado el testimonio de Alejandro, un oyente que ha relatado la pesadilla que vivió durante una comida con su familia política.Alejandro ha contado que fue víctima de su familia política, a la que ha calificado como "muy guasona", especialmente su suegra. A pesar de que siempre iba preparado para sus bromas cada vez que visitaba la casa de su entonces novia, terminaron por sorprenderlo en una ocasión que se le ha quedado grabada "hace muchos años".El escenario fue una comida organizada para el Día de los Inocentes. Aunque Alejandro ha asegurado que iba "preparadísimo", no pudo anticipar lo que le esperaba en el menú. "Pusieron unos San Jacobos, que yo los vi raros, pero claro, nunca llegué a pensar, y unas croquetas también", ha ...

Ecoutez Olivier Dauvers : les secrets de la conso du 13 mars 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Andrew Yee, MD Multiple myeloma can feel unfamiliar and overwhelming at first, but today's advances tell a much brighter story. In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it's diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Multiple myeloma Amyloidosis Autologous stem cell transplantation CAR T-cell therapy Immunotherapy fact sheet Clinical Trial Support Center Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson. The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

Send a textIn this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa' clinical pipeline and strategic direction. He outlines the company's plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the Phase 1 study of Lira‑Cel, Anixa' CAR‑T therapy for ovarian cancer, observed in a terminally ill patient population. Dr. Kumar also details key protocol enhancements in the ongoing Phase 1 trial, to help steer the program toward potentially groundbreaking curative outcomes. Finally, supported by Anixa's capital‑efficient business model, Dr. Kumar notes that the expansion of clinical data in 2026 could drive meaningful opportunities for pharma partnerships and further validate the company's broader immunotherapy strategy.

Dr. Ivan Horak, Founder and CEO of Tikva Allocell, is focused on next-generation allogeneic cell therapies using modified T-cells from healthy donors to make these therapies more scalable, accessible, and affordable. Using virus-specific T-cells, this approach is showing effectiveness against solid tumors, which are difficult for traditional CAR-T therapies to treat. The primary target is an antigen found particularly in Epstein-Barr virus-associated malignancies and is showing potential for treating autoimmune diseases as well as cancer. Ivan explains, "Cell therapy has a long history. We started with many scientists, but probably the godfather of the technology, Zelig Eshhar, who's not with us anymore. He passed away last year. The idea behind that was to use patient cells and modify them and use them as a fighter against the cancer. But over time, we realized over the last two decades that it's very useful, very successful in the treatment of hematologic malignancies, but it's very expensive and labor-intensive. The question was how to enhance this technology and bring it to more patients in a friendly and affordable way." "The second generation are therapies where we are using healthy people's cells, primarily T-cells, but can be NK cells, can be gamma-delta T-cells. And these cells are being modified, and they are infused into a patient. The advantage of this technology is that patients are identified, and the provider can request the cell from different biotechnology companies, which can be available within the next few days, because from one healthy donor, you can make multiple doses for patients."  #TikvaAllocell #CellTherapy #CancerResearch #Immunotherapy #Biotechnology #Biotech #Innovation #ClinicalTrials #AllogeneicTherapy #Allogeneic #SolidTumors #NextGenTherapy #PrecisionMedicine #CellTherapy #CART #Oncology #ImmuneOncology #CellandGeneTherapy tikvaallocell.com Download the transcript here

Dr. Ivan Horak, Founder and CEO of Tikva Allocell, is focused on next-generation allogeneic cell therapies using modified T-cells from healthy donors to make these therapies more scalable, accessible, and affordable. Using virus-specific T-cells, this approach is showing effectiveness against solid tumors, which are difficult for traditional CAR-T therapies to treat. The primary target is an antigen found particularly in Epstein-Barr virus-associated malignancies and is showing potential for treating autoimmune diseases as well as cancer. Ivan explains, "Cell therapy has a long history. We started with many scientists, but probably the godfather of the technology, Zelig Eshhar, who's not with us anymore. He passed away last year. The idea behind that was to use patient cells and modify them and use them as a fighter against the cancer. But over time, we realized over the last two decades that it's very useful, very successful in the treatment of hematologic malignancies, but it's very expensive and labor-intensive. The question was how to enhance this technology and bring it to more patients in a friendly and affordable way." "The second generation are therapies where we are using healthy people's cells, primarily T-cells, but can be NK cells, can be gamma-delta T-cells. And these cells are being modified, and they are infused into a patient. The advantage of this technology is that patients are identified, and the provider can request the cell from different biotechnology companies, which can be available within the next few days, because from one healthy donor, you can make multiple doses for patients."  #TikvaAllocell #CellTherapy #CancerResearch #Immunotherapy #Biotechnology #Biotech #Innovation #ClinicalTrials #AllogeneicTherapy #Allogeneic #SolidTumors #NextGenTherapy #PrecisionMedicine #CellTherapy #CART #Oncology #ImmuneOncology #CellandGeneTherapy tikvaallocell.com Listen to the podcast here

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Marion Falabrègue and Ajai Chari on their papers published in volume 146 issue 24 of Blood. The work of Dr. Falabrègue and colleagues in "Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation" indicates that iron absorption from the apical surface of enterocytes can be modulated through manipulation of the hepcidin-DMT1 interaction, opening new avenues for research and therapeutic manipulation. "Talquetamab plus daratumumab in multiple myeloma" features a phase 1b/2 trial of 65 heavily pretreated patients with MM, where Chari et al combined daratumumab and talquetamab, a GPRC5D-targeting bispecific antibody, reporting depletion of CD38-expressing regulatory T cells following daratumumab and impressive efficacy, with an 80% overall (57% complete) response rate and median progression-free survival of 23.3 months. This regimen is now being evaluated in a phase 3 trial. 

Welcome to OncLive On Air®! I'm your host today, Kyle Doherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine. In our exclusive interview, Dr Smith discussed CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults. _____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Maybe you've heard of CAR-T cells, a type of cell you have in your body that is supercharged in a lab and put back in to fight things like cancer. Biomedical engineering expert Jeremy Green at Johns Hopkins and colleagues … There's a new technique that may revolutionize one type of T cell therapy, Elizabeth Tracey reports Read More »

CAR-T cells are a type of immune cell that have proven very effective for treating some types of cancer, yet limitations to their use exist. Biomedical engineering expert Jordan Green at Johns Hopkins says limitations including lengthy time and expense … Can an injectable particle help supercharge your T cells? Elizabeth Tracey reports Read More »

The price you see online might not be the real price. A new investigation found that Instacart was quietly running pricing experiments—charging different customers different prices for the same groceries at the same time. This week, Paul and Goldy talk with Groundwork Collaborative Executive Director Lindsay Owens about how companies are using AI and massive data sets to run experiments on consumers—testing exactly how much each of us is willing to pay. And if every shopper sees a different price, one big question follows: Do markets still work the way economists say they do? Lindsay Owens is the Executive Director of the economic think tank Groundwork Collaborative and author of the forthcoming book, GOUGED: The End of a Fair Price in America. Further Reading:  Same Cart, Different Price: Instacart's Price Experiments Cost Families at Checkout We Had 400 People Shop For Groceries. What We Found Will Shock You. Gouged: The End of a Fair Price--and What That Means for Your Wallet Social Media: BlueSky: @lindsayowens.bsky.social Instagram: @lindsayowensphd TikTok: @lindsayowensphd Twitter: @owenslindsay1 BlueSky: @groundwork.bsky.social Twitter: @Groundwork Organizations developing policy on surveillence pricing:  American Economic Liberties Project Economic Security Project Tech Equity Consumer Reports  More Perfect Union Website: http://pitchforkeconomics.com Facebook: Pitchfork Economics Podcast Bluesky: @pitchforkeconomics.bsky.social Instagram: @pitchforkeconomics Threads: pitchforkeconomics TikTok: @pitchfork_econ YouTube: @pitchforkeconomics LinkedIn: ⁠Pitchfork Economics⁠ Twitter: @PitchforkEcon, @NickHanauer Substack: The Pitch

Guest: Dr. Daniel Peeper is a Professor in Functional Oncogenomics at VU University Amsterdam, heading the Department of Molecular Oncology & Immunology and chairing the Research Faculty Council Board at the Netherlands Cancer Institute. His lab employs function-based, genome-wide screens and other advanced technologies to develop concepts for rational combinatorial cancer treatment, targeting both cancer and immune cells more effectively. Featured Products and Resources: Obtain highly purified cells in a single step with the Easy 250 EasySep Magnet. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Genomic Insights into EBV – Researchers used genome sequencing data to identify genetic and lifestyle factors linked to control of persistent Epstein–Barr virus (EBV) infection and its association with autoimmune diseases. Cholinergic Control of B Cells – Acetylcholine signaling in germinal center B cells helps regulate their selection and differentiation to shape high-affinity antibody responses. Targeting Persistent HIV Clones – Persistent HIV reservoir T cell clones resist immune clearance but remain vulnerable to sustained cytotoxic T cell pressure. T Cell Engagers in Autoimmunity – CD19×CD3 and BCMA×CD3 T cell engagers improved disease outcomes in patients with treatment-refractory antisynthetase syndrome and systemic sclerosis. Image courtesy of Daniel Peeper Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Cancer treatment has long been a battle of attrition—surgery, radiation, and chemotherapy have saved countless lives, but for patients with advanced or refractory malignancies, the options remain limited. In recent years, however, a new approach has emerged that harnesses the power of the patient's own immune system to seek and destroy cancer cells with unprecedented precision. An editorial perspective, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” published in Volume 17 of Oncotarget by researchers Uzma Saqib, Monika Pandey, and Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya, Indore, India, provides an overview of this revolutionary therapeutic strategy. The paper presents the current state of CAR-T therapy, its clinical successes, and the formidable challenges that remain before it can fulfill its transformative potential. Full blog - https://www.oncotarget.org/2026/03/10/car-t-cell-therapy-a-revolutionary-approach-to-cancer-treatment/ Paper DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Download the transcript here

Ian Crosbie, CEO of Sequana Medical, identifies the incidence of liver cirrhosis and the complication of liver ascites, which causes significant fluid buildup in the belly that severely impacts a patient's quality of life. Standard treatment requires repeated hospital visits to drain the fluid. The alfapump developed by Sequana is a fully implanted device that continuously drains ascites into the bladder for natural excretion, eliminating the need for drainage procedures. Ian explains, "Liver ascites is a complication of liver cirrhosis, a serious condition where the liver becomes badly scarred. As a result, the fluid accumulates in the belly, often five to ten liters of fluid. And as you can imagine, this causes huge swelling of the belly and major clinical problems, and obviously dramatically impacts the quality of life of these patients. Problems can include instability and falling. You can imagine with all that weight out front. The swelling of the belly causes difficulty eating, breathing, sleeping, and functioning."   "So we're in an era of AI and targeted cancer therapies, CAR-T, and things like that. But the standard of care for these patients is to let them build up five to ten liters of fluid in their bellies, then bring them into hospital, stick a big needle in them, drain them over the course of five to seven hours, send them away, and then the moment they leave hospital, they start to reaccumulate that fluid again, and the process starts all over. That is a procedure known as paracentesis. Not only is it, as you can imagine, a painful, burdensome, and traumatic procedure, but in the days leading up to the procedure, the days and weeks as the fluid starts to accumulate, all those impacts on quality of life and clinical complications occur. And so that is why we developed alfapump to stop the buildup of fluid in the belly and to stop all of those problems and to stop those regular visits to the hospital." #SequanaMedical #MedicalDevices #LiverDisease #HealthcareInnovation #PatientCare #MedTech #Alfapump #DigitalHealth #ChronicDisease #QualityOfLife #HealthTech #MedicalBreakthrough sequanamedical.com Listen to the podcast here

Alan interviews Todd Hanson. Todd Hanson is an avid deer hunter - who decided to design an improved deer cart. He invented an innovative deer cart that easily carries game and gear, but also installs without unloading to the hitch hauler on the back of a vehicle. His Compass Cart carriers gear of all types over rough terrain. Make sure to subscribe to the podcast at Apple Podcasts, or wherever you get your podcasts, so you won't miss a single episode. website:  www.CompassCarts.com

Medical researchers say New Zealanders are missing out on a transformative cancer treatment that's been proven to make a difference. It's called CAR T-cell therapy. As it stands, Kiwis have to travel thousands of kilometres overseas to receive this treament, which in and of itself is complex and costly. The Malaghan Institute of Medical Research is spearheading an awareness campaign about CAR T-cell therapy this month, and clinical director Professor Robert Weinkove joins me now to discuss it.

Pour écouter mon podcast Choses à Savoir:Apple Podcast:https://podcasts.apple.com/fr/podcast/choses-%C3%A0-savoir-culture-g%C3%A9n%C3%A9rale/id1048372492Spotify:https://open.spotify.com/show/3AL8eKPHOUINc6usVSbRo3?si=e794067703c14028----------------------------La Chine bat son record de production de charbon… tout en annonçant une future taxe carbone nationale. Entre impératifs économiques et engagements climatiques, l'équilibre est fragile.Traduction :China breaks its coal production record—just as it pledges a future national carbon tax. A balancing act between growth and climate promises. Hosted on Acast. See acast.com/privacy for more information.

Episode #372 – Why Your Abandoned Cart Flow Won't Recover Every Sale Cart abandonment automations are powerful - but they're not a magic net that catches every abandoned cart you see in Shopify. If you've ever opened your Shopify analytics, seen a huge list of abandoned carts, and thought "Why aren't we getting all of these sales back?" - this episode will reset your expectations fast. Because here's the truth: an abandoned cart is not the same thing as a lost sale. In this episode, I explain what cart abandonment actually represents, why recovery rates are naturally lower than many founders expect, and what metrics really matter when evaluating the performance of your abandoned cart flow. Instead of obsessing over the carts you didn't recover, you'll learn how to measure success based on the revenue your automations consistently bring back over time. You'll learn: • Why an abandoned cart doesn't necessarily represent a guaranteed purchase • The real difference between cart abandonment and checkout abandonment • Why most shoppers add items to their cart without immediate buying intent • What normal abandoned cart recovery rates actually look like • The benchmarks high-performing brands typically achieve • The key levers that improve abandoned cart flow performance: timing, messaging, trust signals, and buyer intent alignment • Why the goal isn't eliminating cart abandonment - it's capturing the right buyers at the right moment Abandoned cart flows aren't designed to save every sale. They're designed to quietly recover the buyers who were already close - and when your automation is doing that consistently, it's working exactly as it should. Check out the accompanying blog post here: https://joyjoya.com/blogs/podcast/cart-abandonment-are-your-revenue-recovery-rates-healthy Work with Joy Joya: https://joyjoya.com

Pour écouter mon podcast Choses à Savoir:Apple Podcast:https://podcasts.apple.com/fr/podcast/choses-%C3%A0-savoir-culture-g%C3%A9n%C3%A9rale/id1048372492Spotify:https://open.spotify.com/show/3AL8eKPHOUINc6usVSbRo3?si=e794067703c14028----------------------------La Chine bat son record de production de charbon… tout en annonçant une future taxe carbone nationale. Entre impératifs économiques et engagements climatiques, l'équilibre est fragile.Traduction :China breaks its coal production record—just as it pledges a future national carbon tax. A balancing act between growth and climate promises. Hosted on Acast. See acast.com/privacy for more information.

Venha visitar a nossa Loja:https://iconografia-da-historia-3.myshopify.com/?utm_medium=product_shelf&utm_source=youtubeSiga nosso canal de CORTES:https://www.youtube.com/@IconografiadaHistoria-cortesE siga também nosso canal parceiro "CAFÉ E CAOS TV" apresentado pelo nosso querido Fernandão e Agnes Andradehttps://www.youtube.com/@CafeecaostvAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhNos acompanhe no Spotify @iconocastSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Fernando ZenerattoDireção: Fernando Zeneratto / Joel Paviotti

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: The impressive progression-free survival (PFS) rates observed in the MajesTEC-3 trial, with a PFS of 83.4% at three years. The mechanism of action of teclistamab as a bispecific antibody targeting BCMA and its synergy with daratumumab. Safety profiles, including the management of cytokine release syndrome (CRS) and infection risks, along with the use of IVIG for prophylaxis. The evolving landscape of multiple myeloma therapies, including the role of CAR T-cell therapy versus bispecific antibodies. Join us for this informative discussion that aims to keep healthcare professionals updated on the latest advancements in multiple myeloma treatment. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

Coming up, we explore how CAR-T cell therapy is revolutionising personalised cancer treatment. Plus, how NASA's DART mission tested Earth's asteroid defence, what we are learning about the benefits of breastfeeding for mother and baby health, and we delve into the physics behind squeaky shoes... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of the Guns Podcast, Brent Wheat and Roy Huntington take a trip down memory lane—prompted by a literal lightning strike that knocked Roy off the grid. Without the internet, the duo discusses what the shooting world was like before the digital age took over. They explore the days when information came from dog-eared magazines, crusty experts at the gun counter and the anticipation of mail-order catalogs. Is the instant gratification of today's "Add to Cart" culture ruining the experience of firearm ownership? Roy and Brent debate the pros and cons of the digital revolution, arguing that while we are better informed, we may be losing the joy of the "hunt" for gear and knowledge. They also discuss the concept of "sipping vs. gulping" ammunition and why the paralysis of choice might be hindering new shooters. Tune in for a nostalgic look at gun culture, a challenge to take a "digital detox," and some laughs about the way things used to be. Whether you remember ordering from the Sears Wish Book or you've only ever bought gear on Amazon, this episode offers a fresh perspective on slowing down and enjoying the range. Key Takeaways • The transition from 'analog' shooting culture (magazines, catalogs, word-of-mouth) to the digital age. • How the ease of internet purchasing removes the anticipation and appreciation of acquiring new gear. • The concept of 'Potato Chip Information'—consuming vast amounts of data without retaining depth or value. • The loss of institutional knowledge as the 'old guys' at the gun counters disappear. • The difference between 'sipping' ammunition for precision and enjoyment versus 'gulping' through mag dumps. • The benefits of a 'Digital Detox' to reset your attention span and appreciation for the outdoors. • Why owning unique, high-quality firearms is often more satisfying than chasing the latest commodity trends. -- The Guns Podcast is presented by EOTech. EOTECH is the leading manufacturer of electro-optics.  Known for their world-famous holographic weapon sights, EOTECH also provides precision rifle scopes, ruggedized pistol optics, night-vision, thermal, and laser systems to professional and recreational users around the globe.  Visit eotechinc.com -- Have a topic idea or a guest you'd like to see in a future episode? Let us know in the comments or email editor@gunspodcast.us Never miss an episode! Subscribe to our YouTube channel or sign up for our newsletter to get the Guns Podcast delivered straight to your inbox each week. Buy our Merch! Visit Gunspodcast.us

Savannah Guthrie returned to New York City yesterday to The Today Show following the disappearance of her mother, Nancy Guthrie, who has been missing for five weeks. Mark analyzes what this situation could mean for Savannah and her family. In Minnesota, $19 billion went missing due to fraud - where did the money end up? Governor Tim Walz addressed the issue yesterday, but his answers raised more questions. Gayle King has signed a new deal with CBS News. Mark takes your calls! Mark interviews WOR weeknight host Jimmy Failla. Iran is seeking new leadership after the U.S. deposed the ayatollah. There is talk of his son, Mojtaba Khamenei, succeeding him. Democrats continue to oppose President Trump's actions, including the war in Iran, which Jimmy tries to make sense of.

Savannah Guthrie returned to New York City yesterday to The Today Show following the disappearance of her mother, Nancy Guthrie, who has been missing for five weeks. Mark analyzes what this situation could mean for Savannah and her family. In Minnesota, $19 billion went missing due to fraud - where did the money end up? Governor Tim Walz addressed the issue yesterday, but his answers raised more questions. Gayle King has signed a new deal with CBS News. Mark takes your calls! Mark interviews WOR weeknight host Jimmy Failla. Iran is seeking new leadership after the U.S. deposed the ayatollah. There is talk of his son, Mojtaba Khamenei, succeeding him. Democrats continue to oppose President Trump's actions, including the war in Iran, which Jimmy tries to make sense of.See omnystudio.com/listener for privacy information.

Dr. Marcin Kortylewski (Oligonucleotide therapies and applications Section Editor of Molecular Therapy Nucleic Acids) sits down with Dr. Norman Michael Drzeniek and Niklas Kotzian from the Berlin Institute of Health at Charité. Join them as they discuss their new article, mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Jessie, 80 ans, vit en Australie et n'a plus de contact avec sa fille ni ses petits-enfants depuis plusieurs années, après avoir été mise à l'écart de la famille. Elle exprime sa souffrance face à cette rupture et son besoin de comprendre les raisons de cet éloignement. Jessie cherche des conseils pour tenter de renouer le dialogue avec sa fille. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this week's episode, Blood associate editor Dr. Laura Michaelis interviews Drs. Mark Sorial and Emmanuelle Passegue on their articles published in volume 147 issue 7 of Blood. Dr. Sorial discusses "Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium" where he and his team evaluated the prognostic significance of early relapse in a large retrospective cohort. They report a time to relapse of

Christin Godale, Executive Director of LifeSciKY, and Savannah Doliboa, Chief Commercial Officer at CTI and LifeSciKY board member, explore how purpose built infrastructure can unlock the next generation of medical breakthroughs in our latest podcast episode.Together, they discuss why infrastructure is often the missing link in drug development, how regional collaboration fuels innovation, and what success looks like when companies outgrow the incubator and scale locally. The conversation also shows the human side of ecosystem building by focusing on investing in people, nurturing talent, and turning scientific breakthroughs into real world impact.LifeSciKY is a mission driven hub designed to lower barriers for startups, accelerate early research, and strengthen Northern Kentucky's biotech ecosystem. Through affordable wet lab space, shared equipment, workforce development, STEM education, and community partnerships, it gives innovators the support they need to move discoveries from bench to patient.00:30 An overview of LifeSciKY as a mission driven life sciences hub supporting early stage innovation.01:45 Christin and Savannah share the vision behind LifeSciKY and how it benefits the region.04:00 How the lack of wet lab space stalled regional growth and why infrastructure is essential to moving medicine forward.06:45 Who LifeSciKY Is built for: startups, hybrid AI companies, and entrepreneurs looking to turn science into viable products.08:25 What success looks like for biotech, including formation, fundraising, and scaling beyond the incubator.10:15 How connecting academia, hospitals, industry, and government is building a regional life sciences ecosystem. 12:20 Affordable access, nonprofit mission, and hands on support sets LifeSciKY apart from other incubators.14:20 How multiple years of state support and leadership brought LifeSciKY to its grand opening.18:10 Workforce development and STEM outreach are building the next generation of life sciences talent.22:00 The future of LifeSciKY and why Northern Kentucky could become a biotech hub.23:10 Highlighting a LifeSciKY company developing more accessible CAR T therapies for children.25:00 Ways founders, students, and community members can engage with LifeSciKY.26:10 Reflections on momentum, mission, and future therapies.28:05 In their closing thoughts, Christian and Savannah explore excellence and growth.

Au sommaire : La guerre en Iran inquiète les marchés financiers, avec des baisses importantes à la Bourse de Paris et en Asie, notamment à cause de la fermeture du détroit d'Ormuz et de la hausse des prix du gaz et du pétrole.L'assurance chômage prévoit un déficit de 2,1 milliards d'euros cette année en raison de la dégradation du marché de l'emploi et des prélèvements exceptionnels du gouvernement.L'écart de rémunération entre les hommes et les femmes cadres s'est accentué, atteignant 16% en 2025 contre 12% en 2026, notamment à cause de la sous-représentation des femmes dans les postes les mieux rémunérés.Les cours de l'or et de l'argent sont en baisse, les investisseurs se tournant vers le dollar américain comme valeur refuge.La Commission européenne va présenter des propositions sur le "Made in Europe" pour se protéger de la concurrence chinoise.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this March mailbag episode of Art Ed Radio, Tim Bogatz is joined by Amanda Heyn to give some advice for the upcoming NAEA National Convention and answer a variety of other questions. From light topics like underrated artists to heavier discussions about career uncertainty, this episode again offers some real talk about the issues art teachers are facing right now. The episode wraps up with a look at the State of Art Ed survey, including discussions about curriculum, behavior management, and showcasing student artwork. Resources and Links Join the Art of Ed Community See all of the Community Events that Tim and Amanda mentioned! Check out the State of Art Ed results Making the Most of Your Conference Experience Getting Started Teaching Art on a Cart PRO Pack How to Work Smarter, Not Harder with Art on a Cart

Audio roundup of selected biopharma industry content from Scrip over the business week ended Feb.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Zealand CEO calls for end to weight loss Olympics; MSD on AI-assisted pipelines; Bruce Levine's CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LTCVEH6JLFGRXBOQCFW6V72NVI/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Cancer is not a foreign invader. It is a failure of defense.  In this episode, Dr. Patrick Soon-Shiong, surgeon, scientist, inventor and one of the most influential figures in modern medicine, lays out a radical idea: your body already knows how to defeat cancer. The question is whether we are activating it… or suppressing it.  Born in apartheid South Africa and driven by what he calls a duty to fight for the underdog, Dr. Soon-Shiong went from performing complex surgeries in Los Angeles to inventing Abraxane, a breakthrough nanoparticle chemotherapy now used worldwide. But he believes chemotherapy was only chapter one, Chapter two is immunity.  He breaks down the role of the 450 million year old Natural Killer cell and why it may be the missing piece in cancer prevention, then dives into IL-15, once ranked the most promising molecule to cure cancer and now approved in 33 countries, with new ground in lung cancer treatment in Saudi Arabia.  Dr. Soon-Shiong also shares his warning of a coming "pandemic of cancer," the controversy around COVID vaccine development, the overlooked $10 blood test hidden inside routine labs that predicts mortality risk, and how camel nanobodies, AI and robotics may democratize treatments that once cost $1 million.  If you care about longevity, cancer prevention, or the future of medicine, this episode matters.    Timestamps:  00:00 – First impressions of the Middle East and the crisis of trust  08:17 – What cancer really is and the role of the Natural Killer cell  14:08 – The warning: a possible pandemic of cancer in young people  16:47 – The T-cell COVID vaccine controversy  24:40 – IL-15: ranked the #1 molecule to cure cancer  29:07 – Breaking news: approvals in 33 countries and Saudi Arabia  31:06 – Immunity, aging, and the link to longevity  37:53 – The $10 blood test hidden in plain sight for 30 years  39:28 – Why camels and sharks don't get cancer  44:32 – From apartheid South Africa to billionaire inventor  48:13 – Turning $1 million CAR-T therapy into a $25,000 robotic solution  50:33 – Why the Middle East could lead the next biotech revolution    Follow Spencer Lodge on Social Media:  https://www.instagram.com/madeindubaipodcast/?hl=en  https://www.instagram.com/spencer.lodge/?hl=en  https://www.tiktok.com/@spencer.lodge  https://www.linkedin.com/in/spencerlodge/  https://www.youtube.com/c/SpencerLodgeTV  https://www.facebook.com/spencerlodgeofficial/  https://www.facebook.com/profile.php?id=61586194260076    Follow Dr. Patrick Soon-Shiong on Social Media:  https://x.com/DrPatrick

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.

La ciencia española lidera mundialmente los trasplantes. Amelia Escolano, desde Filadelfia, investiga una innovadora vacuna contra el VIH que induce anticuerpos neutralizantes y muestra potencial para otros virus mutantes. España también deposita semillas de olivo en Svalbard para preservar la diversidad genética agrícola. Las enfermedades raras encuentran esperanza en la terapia génica. La Fundación Columbus impulsa esta técnica que corrige información genética defectuosa con éxitos en patologías monogénicas, aunque el coste y la falta de ánimo de lucro para casos ultrarraros son desafíos. Las terapias CAR-T, llamados "medicamentos vivientes", prometen contra el cáncer al modificar células T del paciente para atacar tumores. Tenerife registra un enjambre sísmico en el Teide, bajo vigilancia y sin indicios de erupción inminente. En economía, la inflación española se mantiene en el 2.3% en febrero (subyacente 2.7%), superando la media europea, afectando la competitividad con alimentos ...

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families. In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR T-cell therapy Clinical Trial Support Center CAR T-Cell Therapy: A Path of Hope and Healing Video Series Bloodline Breakthroughs: innovations and inspiration video podcast: CAR T-cell Therapy Hematology Horizons vlog: CAR T-Cell Therapy and the Patient Experience CAR T-Cell Therapy: Side Effects video Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; Novartis Pharmaceuticals Corporation. The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Bhavana (Tina) Bhatnagar, DO—Associate Professor of Medicine at the WVU Cancer Institute—shares her journey from academic centers to rural West Virginia, where she's working to expand access and improve outcomes for underserved communities. We talk about what high-quality rural cancer care really takes: overcoming transportation and financial barriers, navigating limited specialty resources, building community-based clinical trials, and expanding access to innovations like CAR T—powered by strong multidisciplinary teams.Key takeaway: the best care starts with understanding the person behind the patient.

Convidada: Marina Pera, analista sênior de risco político da consultoria Control Risks no México. O chefão do cartel Jalisco Nova Geração, um dos mais violentos e poderosos grupos criminosos organizados do México, foi morto no último domingo (22). O megatraficante Nemesio Oseguera Cervantes, conhecido como "El Mencho", foi baleado em uma operação das forças de segurança mexicanas: os agentes monitoraram os passos de sua namorada até uma cabana em Tapalpa, na região montanhosa do estado de Jalisco, onde se deu o confronto. A morte de El Mencho foi o gatilho para uma reação violenta do grupo organizado. Ataques foram registrados em 20 estados mexicanos: criminosos incendiaram veículos, bloquearam rodovias, fecharam escolas e espalharam pânico. O número de mortos já passa de 70, entre policiais, agentes penitenciários e integrantes do cartel. O governo mobilizou mais de 10 mil militares para conter a violência. A morte do chefe do Jalisco Nova Geração abre uma nova fase de incertezas no México, afirma Marina Pera, analista sênior de risco político da consultoria Control Risks no México. Em entrevista a Natuza Nery, ela descreve como El Mencho mantinha seu poder e cultivava uma imagem messiânica diante de seu grupo. Marina também explica por que a queda de uma liderança desse tamanho pode desencadear uma avalanche na estrutura do narcotráfico e nas instituições oficiais mexicanas.

Immune discusses how tattoo ink accumulates in lymph nodes, promotes inflammation and influences response to two different vaccines. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server IL-9, CAR T cells and anti-tumor CD8 cells Tattoo ink, inflammation and vaccines Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.  

This month, the gals welcome back their pal Robbie Knutsen to scream about mermaids in public, niche children's birthday party themes, Pentagon plugs, twisted panties, crocodile tears, and modern grave robbing. Tune in for February's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.   0:00 Introduction 11:26 Headlines 45:24 Coven Confessions 1:16:15 Coroner Corner

Ever notice how your Etsy shop gets a lot of "Add to Cart" activity… but not a lot of purchases? You're not alone. In this episode, we break down why shoppers use "Add to Cart" so often in ecommerce , and why it doesn't mean they're ready to buy. Here is that creepy video I talked about - brace yourself. - https://www.youtube.com/watch?v=Ntf5_ue2Lzw&t=294s Join my skool group if your not too creeped out - https://www.skool.com/grow-my-etsy-shop-3051  

AITA: For not giving someone my cart at Aldi's, DIRT ALERT: Gene Hackman estate update, an appreciation moment for "The Birdcage," and Jason's upcoming junket trip to Beverly HillsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Pre-Launch Strategy That Changes Everything What if your audience was already excited to buy before you ever opened the cart? That's the dream, right? No scrambling in the final hours. No sending more emails than you planned. No pushing harder than feels good and still wondering why it's not converting. I'm sitting down with Brenna McGowan, launch strategist and creator of Anticipation Marketing, to talk about the phase of launching most people skip over entirely. And honestly, it's the phase that makes or breaks your results. Here's what I've learned from my own launches and from watching thousands of my students do theirs: most people think they're doing the pre-launch part right. They mention what's coming in the P.S. of an email. They post about it on social and put up a waitlist. They feel like they're doing everything they're supposed to be doing. But then the cart opens and it still feels harder than it should. They're white-knuckling their way through launch week, and by the end of it, they're exhausted and wondering what went wrong. Is it the offer? Is it the audience? Is it just harder to sell right now? Usually, it's none of those things. It's the pre-launch. And that's what we're fixing today. RESOURCES MENTIONED IN THIS EPISODE: You've built something real. Revenue, audience, offers that work. But the results still don't match what you know you're capable of. The Revenue Consistency Formula is a FREE Live training for six-figure female founders who are done with inconsistent results and ready to understand what's out of sync so their messaging, offers, and lead generation can finally work together. Click here to register now. Learn More About Brenna McGowan Find Brenna McGowan on Instagram The Pre-Launch Plan Program HERE ARE THE 3 KEY TAKEAWAYS FROM THIS EPISODE: 1️⃣ A Waitlist Is Not a Pre-Launch — Posting "join the waitlist" isn't warming your audience up in the way you think it is. A real pre-launch builds belief in the problem, belief in the solution, and belief that you are the person to help them get there. When that's in place, you don't have to convince anyone when the cart opens. They're already in. 2️⃣ Sell the Process, Not the Program — During pre-launch, you shouldn't be talking about your course or your offer. Your job is to get your audience to believe in the method behind it. Brenna calls this belief-shifting, and it's the difference between an audience that's ready to buy and one that stays on the fence. 3️⃣ Anticipation Beats Urgency — Emphasizing the countdown used to work, but not anymore. People have been burned by courses and programs that didn't deliver, and they've lost trust in others and in themselves. What works now is building genuine excitement and curiosity so your audience is leaning in and asking when they can buy instead of feeling pushed into a decision. MORE FROM ME Follow me on Instagram @amyporterfield SUBSCRIBE & REVIEW If you loved this episode, please take a moment to subscribe and leave a review on Apple Podcasts! Your support helps us reach more entrepreneurs who need these insights.

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices